Announcement from PREDI-LYNCH PREDI-ROUNDS - September 8th 2026
Please find below a Save the Date for PREDI-ROUND I, the public opening session of the first PREDI-LYNCH Annual Meeting and General Assembly, taking place in Bratislava on Tuesday, 8 September 2026, from 14:00 to 15:00 CEST.
The moderated roundtable will explore expectations, challenges and trial-specific implications for the PREDI-LYNCH and PREDI-ENDO clinical trials, with perspectives from clinical trial leaders, a patient representative and a health-policy expert.
The session will be held in a hybrid format, with the possibility to attend in person or online. Please feel free to share this invitation with relevant colleagues, clinicians, researchers, patient representatives, policy-makers and other stakeholders within your networks.
Kind regards,
Mev Domínguez Valentin, PhD
PREDI-LYNCH Coordinator
Department of Tumor Biology
Institute for Cancer Research
About PREDI-LYNCH:
PREDI-LYNCH homepage (predi-lynch.eu)
PREDI-LYNCH (oslocancercluster.no)
Press Release:
PREDI-LYNCH - Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome
PREDI-LYNCH stands for “Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome.” The project started in 2025 and runs until 2031, with 28 partners in 16 European countries. It is coordinated by Mev Dominguez-Valentin at Oslo University Hospital (OUS) and funded through the EU's Horizon Europe Cancer Mission with 160 mill NOK.
People with Lynch syndrome have an inherited defect in DNA mismatch-repair genes, which substantially increases their risk of certain cancers, particularly colorectal cancer, endometrial (uterine) cancer and cancers of the urinary tract. Currently, surveillance relies heavily on procedures such as regular colonoscopy. PREDI-LYNCH is investigating whether cancers can instead be detected earlier using liquid biopsies—for example, blood or urine samples—combined with molecular analyses and AI.
The idea is essentially: blood/urine sample → detect molecular traces of cancer → AI/multi-omics analysis → identify cancer at a very early stage.
An important part of the project is to determine whether these less-invasive tests can eventually complement or perhaps reduce the need for some of today's invasive surveillance procedures.
The project is led from Oslo by Mev Domínguez Valentin at the Institute for Cancer Research. The University of Oslo and Oslo Cancer Cluster are also Norwegian partners.